Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase

Roberto Latagliata, Chiara Montagna, Raffaele Porrini, Ambra Di Veroli, Sabrina Crescenzi Leonetti, Pasquale Niscola, Fabrizio Ciccone, Antonio Spadea, Massimo Breccia, Luca Maurillo, Angela Rago, Francesca Spirito, Michele Cedrone, Marianna De Muro, Marco Montanaro, Alessandro Andriani, Antonino Bagnato, Enrico Montefusco, Giuliana Alimena

Research output: Contribution to journalArticle

Abstract

At present, very few data are available on deferasirox (DFX) in the treatment of patients with Philadelphia-negative myeloproliferative neoplasms in fibrotic phase (FP-MPN) and transfusion dependence. To address this issue, a retrospective analysis of 28 patients (22 male and 6 female) with FP-MPN and iron overload secondary to transfusion dependence was performed, based on patients enrolled in the database of our regional cooperative group who received treatment with DFX. DFX was started after a median interval from diagnosis of 12.8 months (IR 7.1-43.1) with median ferritin values of 1415 ng/mL (IR 1168-1768). Extra-hematological toxicity was reported in 16 of 28 patients (57.1%), but only two patients discontinued treatment due to toxicity. Among 26 patients evaluable for response (≥6 months of treatment), after a median treatment period of 15.4 months (IR 8.1-22.3), 11 patients (42.3%) achieved a stable and consistent reduction in ferritin levels <1000 ng/mL. As for hematological improvement, 6 of 26 patients (23%) showed a persistent (>3 months) rise of Hb levels >1.5 g/dL, with disappearance of transfusion dependence in four cases. Treatment with DFX is feasible and effective in FP-MPN with iron overload. Moreover, in this setting, an erythroid response can occur in a significant proportion of patients.

Original languageEnglish
Pages (from-to)643-9
Number of pages7
JournalEuropean Journal of Haematology
Volume96
Issue number6
DOIs
Publication statusPublished - Jun 2016

Keywords

  • Aged
  • Benzoates
  • Blood Transfusion
  • Chelation Therapy
  • Erythrocyte Indices
  • Erythropoiesis
  • Female
  • Fibrosis
  • Follow-Up Studies
  • Humans
  • Iron Chelating Agents
  • Iron Overload
  • Male
  • Middle Aged
  • Myeloproliferative Disorders
  • Retrospective Studies
  • Treatment Outcome
  • Triazoles
  • Journal Article

Fingerprint Dive into the research topics of 'Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase'. Together they form a unique fingerprint.

  • Cite this

    Latagliata, R., Montagna, C., Porrini, R., Veroli, A. D., Leonetti, S. C., Niscola, P., Ciccone, F., Spadea, A., Breccia, M., Maurillo, L., Rago, A., Spirito, F., Cedrone, M., De Muro, M., Montanaro, M., Andriani, A., Bagnato, A., Montefusco, E., & Alimena, G. (2016). Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. European Journal of Haematology, 96(6), 643-9. https://doi.org/10.1111/ejh.12674